ICLR (ICLR) Stock Price & Analysis
ICLR (ICLR) fell 0.28% to USD 151.82 as of June 10, 2026 at 03:27 UTC, according to Nexqual real-time market data.
ICLR last closed at USD 152.24; the session ranged USD 150.32–156.09 on volume of 1,194,465 shares. Market capitalization is $11.62B, with a 52-week range of USD 66.57–211 (NMS). Source: Nexqual, June 10, 2026 at 03:27 UTC.
Key Statistics (as of June 10, 2026 at 03:27 UTC)
| Price | USD 151.82 |
|---|---|
| Change | ▼ 0.28% (down) |
| Previous Close | USD 152.24 |
| Open | USD 152.93 |
| Day Range | USD 150.32 – 156.09 |
| 52-Week Range | USD 66.57 – 211 |
| Volume | 1,194,465 shares |
| Market Cap | $11.62B |
| Exchange | NMS |
Technical Analysis (ICLR)
Nexqual's technical model rates ICLR "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 03:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 72.32 (overbought) |
| vs SMA50 | Above (USD 119.36) |
| MACD | 9.58 (positive) |
Analyst Ratings (ICLR)
Wall Street analysts rate ICLR "Buy" based on 16 analysts, with a mean price target of USD 153.25 (range USD 125–180), per Nexqual as of June 10, 2026 at 03:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 153.25 |
| High Target | USD 180 |
| Low Target | USD 125 |
| Buy / Hold / Sell | 8 / 8 / 1 |
Earnings (ICLR)
| Next Earnings Date | 2026-06-09 |
|---|---|
| EPS Estimate | USD 2.43 |
| Revenue Estimate | $2.00B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 2.52 vs est 3.11 ▼ miss |
| 2025-09-30 | USD 3.31 vs est 3.28 ▲ beat |
| 2025-06-30 | USD 3.26 vs est 3.18 ▲ beat |
| 2025-03-31 | USD 3.19 vs est 3.09 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Financials & Fundamentals (ICLR)
| Total Revenue | $8.25B |
|---|---|
| Revenue Growth (YoY) | +12.40% |
| Gross Margin | +26.44% |
| Operating Margin | +10.52% |
| Profit Margin | +2.78% |
| ROE | +2.46% |
| Debt / Equity | 38.68 |
| Current Ratio | 1.1 |
| Total Cash | $647.29M |
| Total Debt | $3.56B |
| Free Cash Flow | $769.35M |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Financial Health Score (ICLR)
Nexqual rates ICLR's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:27 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 26%, operating 11% |
| Balance Sheet | Solid — $647M cash vs $3.56B debt |
| Cash Flow | Solid — FCF $769M, 9% margin |
| Efficiency | Weak — ROE 2%, ROA 3.8% |
Ownership (ICLR)
| Insider Ownership | +0.44% |
|---|---|
| Institutional Ownership | +109.02% |
| Shares Outstanding | 76.57M |
| Float | 76.15M |
| Short % of Float | +3.95% |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Leadership (ICLR)
ICLR is led by Barry Balfe (age 46), CEO & Director, per Nexqual as of June 10, 2026 at 03:27 UTC.
| CEO & Director | Barry Balfe (age 46) |
|---|---|
| Founder & Independent Non-Executive Director | John Climax (age 72) |
| Chief Financial Officer | Nigel Clerkin A.C.A. (age 51) |
| Director of Corporate Communications | Niamh Murphy |
| Vice President of Marketing | David Green |
Major Backers & Investors (ICLR)
Notable institutional backers of ICLR include Artisan Partners Limited Partnership, Harris Associates L.P., Wellington Management, according to Nexqual as of June 10, 2026 at 03:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Artisan Partners Limited Partnership | 19.12% |
| Harris Associates L.P. | 8.65% |
| Wellington Management | 7.74% |
| FMR, LLC | 5.47% |
| Invesco | 5.08% |
| Principal Financial Group, Inc. | 4.34% |
| Brave Warrior Advisors, LLC | 3.92% |
| Massachusetts Financial Services Co. | 3.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.9% |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRL | Charles River Laboratories Inte | USD 189.85 | ▲ 4.69% |
| IQV | IQVIA Holdings, Inc. | USD 186.25 | ▲ 1.53% |
| MEDP | Medpace Holdings, Inc. | USD 466.79 | ▲ 2.76% |
| BRKR | Bruker Corporation | USD 57.24 | ▲ 1.51% |
| WST | West Pharmaceutical Services, I | USD 334.66 | ▲ 6.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:27 UTC. This page is informational and not investment advice.